

Annexures:

Peer Review Publications/Published Abstracts:

- 1 Aekka A., M. V. Hollis, E. M. Boudiab, G. P. Laput, H. Purohit, A. K. Vyas, **Vyas D.** Prehospital Trauma Care Education for First Responders in India, *Journal of Surgical Research* 2015 Aug;197(2):331-8
- 2 Hollis M., Nair A, Chaturvedi LS, Vyas A, Gambhir S, **Vyas D.** miRNA and colorectal cancer, *WJG* July 21, 2015, Volume 21, Issue 27
- 3 Lopez N, Gandhi S, Castro P, Chaturvedi L, Vyas A, **Vyas D.** A second-generation proteasome inhibitor is more potent than Doxorubicin modulating IL-6, pSTAT-3 and NF-kB activity in triple negative breast cancer. *JNN* (in press)
- 4 **Vyas D,** Gieric L, Ching K, Chaturvedi LS, Vyas A: Rapid extensive recurrence of triple negative breast cancer: Is both therapy and cancer biology the culprit. *JOCMR* (in press)
- 5 **Vyas D,** Balakrishnan A. Cell cycle interventions in gastrointestinal cancers. *World Journal of Gastroenterology* (revised)
- 6 **Vyas D.** Surgical Innovation and peer review; *American Journal of Robotic Surgery* (in press)
- 7 G. P. Laput, Aekka A., M. V. Hollis, E. M. Boudiab, H. Purohit, A. K. Vyas, **Vyas D.** Multi-institution study in Prehospital Trauma Care Education for First Responders, *JACS* 2015 Nov (Abstract, in press)
- 8 **Vyas D.*,** Sahil Gambhir*, Hollis M. Vyas A. Gastrointestinal Cancer and Nf-kB, *World Journal of Gastroenterology* 2015 March 21; 21(11): 3174–3183 *co first author
- 9 Lopez N, Gandhi S, Castro P, Chaturvedi L, Vyas A, **Vyas D.** A second-generation proteasome inhibitor is more potent than Doxorubicin modulating IL-6, pSTAT-3 and NF-kB activity in triple negative breast cancer. *JNN* (in press)
- 10 **Vyas D,** Apoorva Aekka, Vyas AK,: Fecal transplant policy and legislation. *World Journal of Gastroenterology.* 2015 Jan 7; 21(1): 6–11.
- 11 **Vyas D,** Gandhi S, Castro P, Chaturvedi L, Lopez N, Vyas A. Iron Oxide Nanoparticle with Doxorubicin and Hyaluronic Acid potentiates the efficacy of Doxorubicin in Triple Negative Breast Cancer Cells through inflammatory pathway, *JNN* Volume 14, Number 1, January 2014, pp. 913-923(11)
- 12 **Vyas D,** Yixin Tong, Chaturvedi LS; The therapeutic effect and mechanism of a novel long-acting second-generation proteasome inhibitor (SGPI) in MDA-MB-231 TNBC cells. *JACS*; October 2014 Volume 219, Issue 4, Supplement, Page e176
- 13 **Vyas D,** Gieric Laput, Vyas AK. Chemotherapy induced inflammation may cause early metastasis. *Oncotarget and therapy* 2014: Jun 12; 7 1015-1023
- 14 **Vyas D,** Ahmed Hozain. Clinical peer review in the United States: History, legal development and subsequent abuse., *World Journal of Gastroenterology*, June 7; 2014 20(21):
- 15 **Vyas D,** Wafa Abdullah. Robotic diligent and expeditious detorsion of gastric volvulus. *Videoscopy-JLAST* and part B January 2014, 24
- 16 Saadeh Y, Vyas A, **Vyas D.** Breast cancer and theranostic nanoparticle, *Journal of Nanoscience and Nanotechnology*, Volume 14, Number 1, January 2014 , pp. 913-923(11)
- 17 **Vyas D,** Castro P, Saadeh Y, Gandhi S, Lopez N, Vyas A. Gastrointestinal diseases and theranostic Nanoparticle, *Journal of Biomedical Nanotechnology*, 2014 (**Impact Factor 7.2**)
- 18 Saadeh Y, **Vyas D.** Nanorobotics: Current Status and Future Directions. *American Journal of Robotic Surgery*, Volume 1, Number 1, June 2014, pp. 4-11(8)

- 19 **Vyas D.** A mission for next generation Robotic Surgery. American Journal of Robotic Surgery, Volume 1, Number 1, June 2014, pp. 38-41(4)
- 20 **Vyas D,** Jay Shah, Vyas Arpita. History of robotics surgery in surgical specialties. American Journal of Robotic Surgery, Volume 1, Number 1, June 2014, pp. 12-20(9)
- 21 **Vyas D,** Cara Weiner. Current status single site robotic surgery and future directions, American Journal of Robotic Surgery, Volume 1, Number 1, June 2014, pp. 55-58(4)
- 22 **Vyas D,** Carter Daniel. Robotics and endoscopy. American Journal of Robotic Surgery, Volume 1, Number 1, June 2014, pp. 48-54(7)
- 23 **Vyas D,** Heidi. L, Vyas A. Stool therapy may become a preferred treatment of recurrent *Clostridium Difficile*. World Journal of Gastroenterology; 19(29), August 2013
- 24 Joshi SS, Vyas AK, **Vyas D,** Kalla R. Reclassifying inflammatory bowel disease with capsule endoscopy in children. J Pediatr (Rio J). 2013 Jul 12.
- 25 **Vyas D.,** Liza Gill. Navigation systems in liver surgery: The new challenge for surgical research. J Laparoendosc Adv Surg Tech A., Vol 23, No. 4, 2013
- 26 **Vyas D,** L. S. Chaturvedi, Mohammad Eldakdouki, Marc Basson, Arpita Vyas, P. S. Mohankumar, Xuefei Huang. A Theranostic Nanoparticle/Curcumin Combination Decreases Doxorubicin-Induced Cytokine Production in MDA-MB-231 Breast Cancer Cells via IL-6/NF-kB pathway. *Journal of Women's Health (Larchmt)* (abstract). 2013
- 27 **Vyas D.,** Garthe C, Vyas A. Limitations of Current Timing and Frequency of Screening Colonoscopy and possible future direction. J Laparoendosc Adv Surg Tech A. 2013.
- 28 **Vyas D,** Phil K, S Kavuturu, Vyas A. Benign Mesothelioma as a rapidly developing Giant Abdominal Cyst. W Journal of Surgical Oncology, 2012 Dec 20;10(1):277.
- 29 **Vyas D,** L. S. Chaturvedi, Mohammad Eldakdouki, Marc Basson, Arpita Vyas, P. S. Mohankumar, Xuefei Huang. Novel theranostic nanoparticle use for efficient administration of Doxorubicin in breast cancer cell. *Journal of Women's Health (Larchmt)* (abstract). 2012 Oct;21(10):1008.
- 30 **Vyas D,** Vyas A. Time to detoxify medical literature from Guidelines overdose, *World Journal of Gastroenterology*, 2012 18(26):3331-3335
- 31 Saju Rajan, **Dinesh Vyas,** Cheryl A Woolsey, Andrew T Clark, Richard S Hotchkiss, Timothy G Buchman, Craig M Coopersmith Intestine-specific overexpression of IL-10 improves survival in polymicrobial sepsis, *Shock*. 2008 April; 29(4): 483-489. (Impact Factor 2.8)
- 32 Henkie P, **Vyas D,** Amit Basu, Amadeo Marcos, Parmjeet Randhawa, Thomas E. Starzl, and Ron Shapiro., Tan. Cold Heparinized Lactated Ringers with Procaine (HeLP) Preservation Fluid in 266 Living Donor Kidney Transplantations", *Transplantation*, 2007 Apr 27;83(8):1134-6 (Impact Factor 3.8)
- 33 **Vyas D,** Robertson CM, Stromberg PE, Martin JR, Dunne WM, Houchen CW, Barrett TA, Ayala A, Perl M, Buchman TG, Coopersmith CM. Epithelial apoptosis in mechanistically distinct methods of injury in the murine small intestine. *Histology and Histopathology*, 2007 Jun;22(6):623-30 (Impact Factor 2.4)
- 34 **Vyas D.** Conservative management of four days old Boerhaave Syndrome with feeding jejunostomy and Mozapride. *Scandinavian Journal of Gastroenterology*. 2006 Oct;41(10):1242-4. (Impact Factor 2.1)
- 35 **Vyas D,** Javadi P, Dipasco PJ, Buchman TG, Hotchkiss RS, Coopersmith CM. Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. *Am J Physiol Regul Integr Comp Physiol*. 2005 Oct; 289(4) (Impact Factor 3.4)
- 36 Javadi P, Buchman TG, Stromberg PE, Turnbull IR, **Vyas D,** Hotchkiss RS, Karl IE, Coopersmith CM. Iron dysregulation combined with aging prevents sepsis-induced apoptosis. *J Surg Res*. 2005 Sep;128(1):37-44. (Impact Factor 2.4)

- 37 Robertson, Charles M; Stromberg, Paul; **Vyas, Dinesh**; Martin, James; Sherman, Benjamin; Buchman, Timothy; Coopersmith, Craig; Hotchkiss, Richard Identifying the optimal method to quantify gut apoptosis in critical illness.: 147-T. *Critical Care Medicine. Society of Critical Care Medicine 35th Critical Care Congress San Francisco, California, USA January 7-11, 2006.*
- 38 Rajan, Saju; **Vyas, D**; Buchman, T G; Coopersmith, C M; Hotchkiss, R S Intestinal specific over expression of IL-10 improves survival in a polymicrobial model of sepsis: 104-T. *Critical Care Medicine. Society of Critical Care Medicine 35th Critical Care Congress San Francisco, California, USA January 7-11, 2006.*